A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia

Schizophrenia Research

Volumn 147, Issue 1, 2013, Pages 201-202

  Baheti, Tushar ^a   Nischal, Anuradha ^a   Nischal, Anil ^a   Khattri, Sanjay ^a   Arya, Amit ^a   Tripathi, Adarsh ^a   Pant, K K ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; OLANZAPINE;

ADD ON THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PYRAZOLES; SCHIZOPHRENIA; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877149397     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.03.017     Document Type: Letter

References (8)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S.A., Abbasi S.H., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 2007, 90:179-185.
2. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
3. Muller N., Schwarz M.J. Role of the cytokine network in major psychoses. Adv. Mol. Cell Biol. 2004, 31:999-1031.
4. Muller N., Schwarz M.J. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 2006, 10:131-148.
5. Muller N., Riedel M., Scheppach C., Branstatter B., Sokullu S., Krampe K., Ulmschneider M., Engel R.R., Müller H.J., Scwarz J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 2002, 159:1029-1034.
6. Muller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., Moller H.J., Klauss V., Schwarz M.J., Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 2010, 121(1-3):118-124. (Aug, E pub 2010, May 31).
7. Rappaport H., Müller N. Immunological states associated with schizophrenia. Psychoneuroimmunology 2001, vol. 2:373-382. Academi Press, San Diego, Calif. 3rd ed. R. Ader, D.L. Felten, N. Cohen (Eds.).
8. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970, 212:11-19.